Latest Mitral stenosis Stories
WEST BRIDGEWATER, Mass., July 10, 2012 /PRNewswire/ -- Cardiosolutions, Inc. an early-stage company focused on the development of an innovative percutaneous system to treat patients with moderate to severe mitral valve regurgitation, today announced it has received a minority investment from Sorin Group (Reuters Code: SORN.MI), a global medical device company and an international leader in the treatment of cardiovascular disease. Cardiosolutions' technology consists of a...
MISGAV, Israel, June 4, 2012 /PRNewswire/ -- MitrAssist Medical Ltd., a developer of minimally invasive products for treating heart disease, announced today that it received ISO 13485:2003 Certification for the design and development of implantable heart valve prostheses. Today's standard treatment for mitral valve regurgitation (MR), blood leakage or backflow into the atrium, is open heart surgery. MitrAssist's unique design preserves the ventricular dynamic mode of...
KIRKLAND, Wash., May 21, 2012 /PRNewswire/ -- Cardiac Dimensions®,( )Inc. today announced that data from its landmark TITAN clinical trial has been published in the most recent issue of the European Journal of Heart Failure. Titled "Treatment of Functional Mitral Regurgitation by Percutaneous Annuloplasty: Results of the TITAN Trial," the manuscript features two-year follow-up data on patients implanted with the CARILLON® Mitral Contour System® as well as one-year follow-up on...
Leading Middle East cardiologists call for adoption of rheumatic heart disease screening and prevention programs at the World Congress of Cardiology Patients with rheumatic heart disease (RHD) are being admitted to hospital too late to prevent the need for heart surgery, according to a new study carried out by doctors in Yemen and presented today at the World Congress of Cardiology. RHD is a devastating consequence of repeated episodes of rheumatic fever. The disease progresses over...
TAVI improves heart function and exercise capacity German researchers report success with transcatheter aortic valve implantation (TAVI) in patients with low-flow, low-gradient aortic stenosis—a special form of aortic stenosis that is difficult to treat. Results published in the April issue of Catheterization and Cardiovascular Interventions, the peer-reviewed journal of the Society for Cardiovascular Angiography and Interventions (SCAI), show that while all-cause mortality was high...
TAVI Improves Heart Function and Exercise Capacity German researchers report success with transcatheter aortic valve implantation (TAVI) in patients with low-flow, low-gradient aortic stenosis—a special form of aortic stenosis that is difficult to treat. Results published in the April issue of Catheterization and Cardiovascular Interventions, the peer-reviewed journal of the Society for Cardiovascular Angiography and Interventions (SCAI), show that while all-cause mortality was high...
KIRKLAND, Wash., Nov. 7, 2011 /PRNewswire/ -- Cardiac Dimensions®, Inc. today announced that an update to its landmark TITAN clinical trial will be given as part of the 23rd annual Transcathether Cardiovascular Therapeutics (TCT) Conference being held at the Moscone Center in San Francisco. Steven L. Goldberg, M.D., the Company's Chief Clinical Officer will deliver a presentation entitled, Cardiac Dimensions CARILLON XE2: Foundational Results and Design Iteration Toward a Pivotal...
KIRKLAND, Wash., Oct. 13, 2011 /PRNewswire/ -- Cardiac Dimensions(®),( )Inc. today announced that it had named sales and marketing executive Omari V. Bouknight its Vice President of Sales and Marketing, effective Oct. 12. He reports directly to President and Chief Executive Officer Rick Stewart. Bouknight has primary responsibility for the commercialization of the CARILLON(®) Mitral Contour System((TM)) throughout Europe. The CARILLON system, which recently received CE Mark approval,...
KIRKLAND, Wash., Oct. 11, 2011 /PRNewswire/ -- Cardiac Dimensions(®),( )Inc. today announced the first patient has been enrolled and successfully treated in the TITAN II clinical trial, a follow-up to the landmark TITAN clinical trial of the Company's CARILLON(®) Mitral Contour System((TM)). TITAN II is a prospective, single-arm clinical trial initiated to further evaluate an enhanced version of the CARILLON system, a novel therapy for treating heart failure patients suffering from...
KIRKLAND, Wash., Sept. 29, 2011 /PRNewswire/ -- Cardiac Dimensions®, Inc. today announced that it has received Conformite Europeenne (CE) Mark approval for a newly enhanced version of its CARILLON® Mitral Contour System(TM), a novel therapy for treating heart failure patients suffering from functional mitral regurgitation (FMR). Receipt of the CE Mark enables Cardiac Dimensions to initiate a commercial launch of the enhanced device in Europe, which the Company noted will begin in...
